Journal of Hematology & Oncology
-
Publication Venue For
- Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.. 15:115. 2022
- Combination strategies to maximize the benefits of cancer immunotherapy.. 14:156. 2021
- COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.. 14:38. 2021
- CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.. 14:26. 2021
- New agents and regimens for diffuse large B cell lymphoma.. 13:175. 2020
- XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.. 13:148. 2020
- Novel therapies are changing treatment paradigms in metastatic prostate cancer.. 13:144. 2020
- Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.. 13:40. 2020
- Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.. 12:70. 2019
- Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.. 11:90. 2018
- miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.. 11:58. 2018
- Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.. 11:29. 2018
- Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.. 11:15. 2018
- Checkpoint inhibitors in hematological malignancies.. 10:103. 2017
- Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.. 10:100. 2017
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.. 10:55. 2017
- Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.. 9:71. 2016
- Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.. 8:109. 2015
- Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.. 8:74. 2015
- TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.. 8:45. 2015
- Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. 6. 2013
- Fact or fiction - identifying the elusive multiple myeloma stem cell. 6. 2013
- Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.. 6:62. 2013
- A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.. 6:17. 2013
- Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.. 5:15. 2012
- Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.. 3:27. 2010